About Vicor
Vicor's Focus
Vicor's PD2i Cardiac Analyzer addresses the growing need for the medical community to accurately risk stratify patients who are at high or low risk of suffering a fatal arrhythmic event. This will lead to a high quality of patient care, the minimization of medical expenses, and enhancing the patient's Quality of Life. Vicor Technologies, has only one competitor, and is uniquely positioned to address this substantial unmet medical need.
A fatal arrhythmic event, Sudden Cardiac Death (SCD) is not a heart attack, which is considered an “internal plumbing problem.” SCD is theorized to be caused by a breakdown of the normal neurological communication pattern between the heart and brain. SCD is swift, unexpected, and asymptomatic. In most cases it leads to death within 5-10 minutes if medical attention is not received. It is estimated that 95% of patients die before receiving appropriate medical attention for an arrhythmic event.
The PD2i algorithm provides a method for evaluating electrophysiological potentials (from electrocardiograms) with a high sensitivity and high specificity used to predict future pathological events i.e. fatal cardiac arrhythmias. The PD2i algorithm detects deterministic, low-dimensional excursions in nonstationary heartbeat intervals. The PD2i algorithm uses an analytic measure that is deterministic and nonlinear. It is based on caused variation in data; does not require data stationarity and actually tracks nonstationary changes in the data. It is sensitive to chaotic as well as nonchaotic, linear data.
The mission of the Vicor drug discovery platform is to focus on the pre-clinical and early clinical development of specific naturally occurring peptides and proteins derived from “state-dependent” physiologies that will revolutionize the treatment of an array of human diseases.